**Star News, Datang Pharmaceutical released a performance forecast, and it is expected that the attributable net profit for the whole year of 2023 will be about 76440,000 yuan.
The announcement explained the reasons for the change in performance:
The net profit in 2023 decreased year-on-year, mainly due to: first, the year-on-year decrease in the ** subsidy received in the current period; Second, in this period, we increased market investment, further expanded sales channels, and increased sales expenses year-on-year; Third, the amount used to purchase bank wealth management products in the current period decreased and the yield of wealth management products decreased, resulting in a decrease in investment income; Fourth, the provision for impairment of inventory decline in the current period increased year-on-year; Fifth, the projects under construction of Datang Pharmaceutical Health Science and Technology Industrial Park have been consolidated one after another, and the depreciation expenses have increased year-on-year.
Datang Pharmaceutical's third quarter report for 2023 shows that the company's main revenue is 14.8 billion yuan, an increase of 20 percent year-on-year38%；Net profit attributable to the parent company was 1045190,000 yuan, a year-on-year decrease of 4781%；Deduct non-net profit of 669570,000 yuan, a year-on-year decrease of 1025%；Among them, in the third quarter of 2023, the company's single-quarter main revenue will be 2506090,000 yuan, a year-on-year decrease of 4081%；Net profit attributable to parent company in a single quarter was -1135590,000 yuan, a year-on-year decrease of 48197%；Non-net profit deducted in a single quarter was -1343460,000 yuan, a year-on-year decrease of 84306%；The debt ratio is 2852%, investment income 110060,000 yuan, financial expenses - 51140,000 yuan, gross profit margin of 7093%。
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you.